SPRINT BTA Stock Overview

A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. More details

SPRINT BTA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (SEK43M)

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Sprint Bioscience AB (publ) Competitors

Alligator Bioscience

OM:ATORX

SEK 71.0m

AcouSort

OM:ACOU

SEK 60.3m

Biovica International

OM:BIOVIC B

SEK 78.2m

Nanologica

OM:NICA

SEK 106.9m

Price History & Performance

Summary of share price highs, lows and changes for Sprint Bioscience
Historical stock prices
Current Share Price	SEK 0.61
52 Week High	SEK 0.67
52 Week Low	SEK 0.60
Beta	-0.62
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0.66%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SPRINT BTA	SE Biotechs	SE Market
7D	-8.2%	6.2%	2.1%
1Y	n/a	1.2%	-2.0%

Return vs Industry: Insufficient data to determine how SPRINT BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how SPRINT BTA performed against the Swedish Market.

Price Volatility

Is SPRINT BTA's price volatile compared to industry and market?
SPRINT BTA volatility
SPRINT BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.9%
Market Average Movement	6.9%
10% most volatile stocks in SE Market	14.7%
10% least volatile stocks in SE Market	4.2%

Stable Share Price: SPRINT BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine SPRINT BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	38	Johan Emilsson	www.sprintbioscience.com

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer.

Sprint Bioscience AB (publ) Fundamentals Summary

How do Sprint Bioscience's earnings and revenue compare to its market cap?
SPRINT BTA fundamental statistics
Market cap	SEK 43.85m
Earnings (TTM)	-SEK 18.28m
Revenue (TTM)	SEK 66.14m

0.7x

P/S Ratio

-2.4x

P/E Ratio

Is SPRINT BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPRINT BTA income statement (TTM)
Revenue	SEK 66.14m
Cost of Revenue	SEK 28.34m
Gross Profit	SEK 37.80m
Other Expenses	SEK 56.08m
Earnings	-SEK 18.28m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.26
Gross Margin	57.16%
Net Profit Margin	-27.63%
Debt/Equity Ratio	0%

How did SPRINT BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/05 22:52
End of Day Share Price	2025/05/05 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sprint Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Siri Ladow	Danske Bank
Johan Unnerus	Redeye